quantisnow
FeedTopReportsPricing
⌘K
Live feed
19:44:30·276d
INSIDERFiling
Blueprint Medicines Corporation logo

Chief Commercial Officer Lee Philina was granted 21,353 shares and returned 50,165 shares to the company, closing all direct ownership in the company (SEC Form 4)

BPMC· Blueprint Medicines Corporation
Health Care
Original source

Companies

  • BPMC
    Blueprint Medicines Corporation
    Health Care

Recent analyst ratings

  • Jun 2UpdateWedbush$129.00
  • Mar 20UpdateMorgan Stanley$100.00
  • Mar 18UpdateWolfe Research-
  • Mar 17UpdateJefferies$135.00
  • Mar 7UpdateScotiabank$150.00
  • Nov 14UpdateJP Morgan$126.00

Related

  • SEC269d
    SEC Form 15-12G filed by Blueprint Medicines Corporation
  • SEC273d
    SEC Form EFFECT filed by Blueprint Medicines Corporation
  • INSIDER276d
    Chief Financial Officer Landsittel Michael returned 51,102 shares to the company and was granted 21,353 shares, closing all direct ownership in the company (SEC Form 4)
  • INSIDER276d
    Director Dable Habib J returned 3,902 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER276d
    Principal Accounting Officer Hurley Ariel was granted 2,460 shares and returned 16,146 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER276d
    Director Tsai John returned 3,902 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER276d
    Director Coats Lonnel returned 6,144 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER276d
    Chief Medical Officer Hewes L. Becker was granted 21,353 shares and returned 50,165 shares to the company, closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022